Alumis Inc ALMS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
-
Alumis to Participate in Upcoming September Investor Conferences
-
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
-
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
-
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
-
Alumis Plans FDA Filing for Plaque Psoriasis Drug After Positive Phase 3 Results
Trading Information
- Previous Close Price
- $6.12
- Day Range
- $6.11–6.40
- 52-Week Range
- $4.37–31.34
- Bid/Ask
- $6.27 / $6.30
- Shares Outstanding
- 129.44M
- Market Cap
- $824.50M
- Volume/Avg
- 557,166 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 95.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 239
- Website
- https://www.alumis.com
Valuation
|
Metric
|
ALMS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.74 |
Price/Sales | 95.55 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALMS
|
|---|---|
Quick Ratio | 6.64 |
Current Ratio | 6.74 |
Interest Coverage | — |
Quick Ratio
ALMS
Profitability
|
Metric
|
ALMS
|
|---|---|
Return on Assets (Normalized) | −64.16% |
Return on Equity (Normalized) | −80.34% |
Return on Invested Capital (Normalized) | −77.93% |
Return on Assets
ALMS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|v#HyCM | LOCK|&qGr | $127B | |||
| Moderna Inc
MRNA
| LOCK|C<!@^$ | LOCK|R<y | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<&x$HQ | LOCK|V?p#$ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|j?k>!Vc | LOCK|^> | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|l?w?Z?? | LOCK|MVG | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|BSjYy& | LOCK|?Y!Z | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|m@^vS@x& | LOCK|nlzB | $27B | |||
| Incyte Corp
INCY
| LOCK|w%B!Yz | LOCK|^! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$hHX&<f | LOCK|<f | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<wKPB> | LOCK|$># | $14B |
United States